Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.

Details

Serval ID
serval:BIB_230A64A8295C
Type
Article: article from journal or magazin.
Collection
Publications
Title
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
Journal
Clinical Cancer Research
Author(s)
Zhang L., Yang N., Conejo-Garcia J.R., Katsaros D., Mohamed-Hadley A., Fracchioli S., Schlienger K., Toll A., Levine B., Rubin S.C., Coukos G.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Publication state
Published
Issued date
2003
Volume
9
Number
1
Pages
264-272
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.Publication Status: ppublish
Abstract
The first tissue-specific angiogenic molecule, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was identified recently in human ovary, raising hopes of developing tumor type-specific angiogenesis inhibitors. In the present study, we analyzed the expression of EG-VEGF mRNA in normal human tissues and ovarian neoplasms by quantitative real-time reverse transcription-PCR. EG-VEGF mRNA was expressed in all ovarian neoplasms examined. No significant difference was identified among benign, low malignant potential neoplasms or stage I ovarian cancer, all of which exhibited 2-fold lower mRNA levels compared with normal premenopausal ovaries. EG-VEGF mRNA levels further decreased in late stage compared with early stage carcinomas (P < 0.05) and were consistently lower in laser capture microdissected tumor islets compared with surrounding stroma. EG-VEGF was undetectable by reverse transcription-PCR in 17 established epithelial ovarian cancer cell lines or in cultured human ovarian surface epithelial cells, whereas it was detected in peripheral blood as well as tumor-infiltrating T lymphocytes. Finally, in contrast to VEGF, EG-VEGF mRNA levels did not correlate with clinical outcome in advanced ovarian carcinoma. These results suggest that EG-VEGF is most likely derived from nonepithelial components of ovarian carcinomas and may play a marginal role in promoting angiogenesis in advanced ovarian carcinoma. We postulate that EG-VEGF-targeted antiangiogenic therapy may prove useful in early stage but not in advanced stage ovarian carcinoma.
Keywords
Angiogenesis Inducing Agents/biosynthesis, Carcinoma/metabolism, Endocrine Glands/metabolism, Endothelial Growth Factors/biosynthesis, Female, Flow Cytometry, Gastrointestinal Hormones/biosynthesis, Humans, Immunohistochemistry, Intercellular Signaling Peptides and Proteins/biosynthesis, Lasers, Lymphokines/biosynthesis, Microscopy, Fluorescence, Ovarian Neoplasms/metabolism, RNA, Messenger/metabolism, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Tissue Distribution, Treatment Outcome, Tumor Cells, Cultured, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Endocrine-Gland-Derived, Vascular Endothelial Growth Factors
Pubmed
Web of science
Create date
14/10/2014 11:42
Last modification date
20/08/2019 13:00
Usage data